2022 World Conference on Lung Cancer (ePosters)-EP11.01-014. Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS

EP11.01-014. Optimizing Targetable Gene Screening by Sequential Multi-platform Detection Applied to Driver-negative mNSCLC Patients Detected by DNA-NGS

Back to course

Pdf Summary

This study aimed to evaluate the value of using multiple traditional platforms to identify targetable gene alterations in patients with metastatic non-small cell lung cancer (mNSCLC) who do not have driver alterations. The researchers collected data from 1926 mNSCLC patients who had undergone DNA next-generation sequencing (NGS) using limited tissue biopsy samples. Of the 494 cases that tested negative for driver alterations, 415 cases were further analyzed using additional traditional platforms such as ARMS-PCR, IHC, FISH, and a mutant gene detection kit. The results showed that 15 of the driver-negative cases had targetable gene alterations, including EGFR mutation, ALK fusion, ROS1 fusion, and MET amplification. Of these cases, 11 patients received targeted therapy and 6 achieved partial response. Additionally, the mutant gene detection kit identified positive cases for EGFR, ALK, MET, RET, and ROS1 alterations. Overall, the study concludes that using a sequential multi-traditional platform in combination with DNA-NGS can improve the accuracy of targetable gene mutation and fusion detection in advanced-stage NSCLC, leading to better treatment outcomes for patients.

Asset Subtitle

Yaxi Wang

Meta Tag

Speaker Yaxi Wang

Topic Pathology - Genomics & Analytics

Keywords

traditional platforms

gene alterations

metastatic non-small cell lung cancer

driver alterations

DNA next-generation sequencing

limited tissue biopsy samples

ARMS-PCR

IHC

FISH

mutant gene detection kit